<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057104</url>
  </required_header>
  <id_info>
    <org_study_id>SBRTplusTACE VS. HR</org_study_id>
    <nct_id>NCT05057104</nct_id>
  </id_info>
  <brief_title>Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy</brief_title>
  <official_title>Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing 302 Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the prognosis and adverse reactions of unresectable hepatocellular carcinoma&#xD;
      receiving stereotactic radiotherapy combined with hepatic arterial chemoembolization and&#xD;
      conversion hepatectomy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 24 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival time</measure>
    <time_frame>From date of randomization until the date of disease progression or date of death from any cause, whichever came first, assessed up to 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation-induced liver injury rates</measure>
    <time_frame>From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reaction</measure>
    <time_frame>From the date of radiotherapy completion until the 4 months after therapy,up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <condition>Conversion</condition>
  <arm_group>
    <arm_group_label>CK-SBRT with TACE group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Conversion hepatectomy after CK-SBRT plus TACE</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Unresectable HCC patients meet surgical criteria after CK-SBRT plus TACE.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unresectable HCC patients were diagnosed by a surgeon and/or radiologist and&#xD;
             oncologist according to the international guidelines for the management of HCC or by&#xD;
             pathology&#xD;
&#xD;
          -  Patients who received SBRT plus TACE have tumor regression, and surgical experts&#xD;
             assess that R0 resection could be achieved&#xD;
&#xD;
          -  CP-A or B classification;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score 0-1;&#xD;
&#xD;
          -  Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;&#xD;
&#xD;
          -  ICG R15≤10%;&#xD;
&#xD;
          -  Normal effective liver volume &gt;30%;&#xD;
&#xD;
          -  patients infected with hepatitis B virus who are treated with adefovir or entecavir;&#xD;
             patients infected with hepatitis C virus whose HCV DNA are negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -the patients receive other treatments (such as targeted treatment, immune checkpoint&#xD;
        inhibitors,etc) after CK-SBRT plus TACE.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuezhang Duan</last_name>
    <phone>+8613621386161</phone>
    <email>duanxuezhang2006@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Sun</last_name>
    <phone>+8613718681094</phone>
    <email>519299998@qq.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020 Jul;70(4):313. doi: 10.3322/caac.21609. Epub 2020 Apr 6.</citation>
    <PMID>32767693</PMID>
  </reference>
  <reference>
    <citation>Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, Tang MY, Jiang HY, Lian ZP, Hou EC, Liang P. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma &gt;5 cm. BMC Cancer. 2016 Nov 3;16(1):834.</citation>
    <PMID>27809890</PMID>
  </reference>
  <reference>
    <citation>Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, Xing H, Xu Y, Shi J, Guo W, Zhou D, Zhang H, Sun H, Huang C, Lu C, Zheng Y, Meng Y, Huang B, Cong W, Lau WY, Cheng S. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. J Clin Oncol. 2019 Aug 20;37(24):2141-2151. doi: 10.1200/JCO.18.02184. Epub 2019 Jul 8.</citation>
    <PMID>31283409</PMID>
  </reference>
  <reference>
    <citation>Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiother Oncol. 2018 Oct;129(1):112-122. doi: 10.1016/j.radonc.2017.11.013. Epub 2017 Dec 9.</citation>
    <PMID>29233562</PMID>
  </reference>
  <reference>
    <citation>Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg. 2004 Aug;240(2):299-305.</citation>
    <PMID>15273555</PMID>
  </reference>
  <reference>
    <citation>Tomonari T, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Okamoto K, Miyamoto H, Muguruma N, Saito Y, Imura S, Bando Y, Shimada M, Takayama T. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports. Medicine (Baltimore). 2020 Oct 16;99(42):e22782. doi: 10.1097/MD.0000000000022782.</citation>
    <PMID>33080748</PMID>
  </reference>
  <reference>
    <citation>Hoffe SE, Finkelstein SE, Russell MS, Shridhar R. Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Control. 2010 Apr;17(2):100-10. Review.</citation>
    <PMID>20404793</PMID>
  </reference>
  <reference>
    <citation>Chiang CL, Chan ACY, Chiu KWH, Kong FS. Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. Front Oncol. 2019 Nov 12;9:1157. doi: 10.3389/fonc.2019.01157. eCollection 2019.</citation>
    <PMID>31799176</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CyberKnife</keyword>
  <keyword>unresectable hepatocelluar carcinoma</keyword>
  <keyword>TACE</keyword>
  <keyword>hepatectomy</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

